[go: up one dir, main page]

MA39170B1 - Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer - Google Patents

Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer

Info

Publication number
MA39170B1
MA39170B1 MA39170A MA39170A MA39170B1 MA 39170 B1 MA39170 B1 MA 39170B1 MA 39170 A MA39170 A MA 39170A MA 39170 A MA39170 A MA 39170A MA 39170 B1 MA39170 B1 MA 39170B1
Authority
MA
Morocco
Prior art keywords
serine
cancer
treatment
threonine kinase
inhibitory compounds
Prior art date
Application number
MA39170A
Other languages
English (en)
Other versions
MA39170A1 (fr
Inventor
Aleksandr Kolesnikov
Steven Do
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MA39170A1 publication Critical patent/MA39170A1/fr
Publication of MA39170B1 publication Critical patent/MA39170B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés de formule (i) dans laquelle r1, x1, x2, x3 et x4 sont, tels que définis dans le présent document, des inhibiteurs de la protéine erk. L'invention concerne également des compositions et des procédés de traitement de troubles hyperprolifératifs.
MA39170A 2013-12-06 2014-12-03 Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer MA39170B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361912905P 2013-12-06 2013-12-06
PCT/US2014/068452 WO2015085007A1 (fr) 2013-12-06 2014-12-03 Inhibiteurs de sérine/thréonine kinase

Publications (2)

Publication Number Publication Date
MA39170A1 MA39170A1 (fr) 2018-04-30
MA39170B1 true MA39170B1 (fr) 2019-05-31

Family

ID=52350292

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39170A MA39170B1 (fr) 2013-12-06 2014-12-03 Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer

Country Status (23)

Country Link
US (5) US9867833B2 (fr)
EP (1) EP3077401B1 (fr)
JP (2) JP6449293B2 (fr)
KR (1) KR102359759B1 (fr)
CN (1) CN106029672B (fr)
AR (1) AR098647A1 (fr)
AU (1) AU2014360455B2 (fr)
BR (1) BR112016012844B1 (fr)
CA (1) CA2932729C (fr)
CL (1) CL2016001368A1 (fr)
CR (1) CR20160309A (fr)
EA (1) EA031243B1 (fr)
IL (1) IL246017B (fr)
MA (1) MA39170B1 (fr)
MX (1) MX368443B (fr)
MY (1) MY176049A (fr)
PE (1) PE20160886A1 (fr)
PH (1) PH12016501071B1 (fr)
SG (1) SG11201604573WA (fr)
TW (1) TWI557126B (fr)
UA (1) UA120506C2 (fr)
WO (1) WO2015085007A1 (fr)
ZA (1) ZA201604461B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014060395A1 (fr) 2012-10-16 2014-04-24 F. Hoffmann-La Roche Ag Inhibiteurs de la sérine/thréonine kinase
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
AU2014360455B2 (en) 2013-12-06 2018-05-10 Genentech, Inc. Serine/threonine kinase inhibitors
JP6487925B2 (ja) 2013-12-30 2019-03-20 ジェネンテック， インコーポレイテッド セリン／トレオニンキナーゼ阻害剤
KR102396710B1 (ko) * 2013-12-30 2022-05-10 어레이 바이오파마 인크. 세린/트레오닌 키나제 저해제
CR20180316A (es) 2015-11-09 2018-10-05 Astrazeneca Ab Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
CA3018406A1 (fr) 2016-04-15 2017-10-19 Genentech, Inc. Procedes diagnostiques et therapeutiques relatifs au cancer
MX2020002553A (es) 2017-09-08 2020-07-22 Hoffmann La Roche Metodos de diagnostico y terapeuticos para el cancer.
US20210008047A1 (en) 2018-02-13 2021-01-14 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
BR112021024546A2 (pt) * 2019-06-06 2022-02-08 Hutchison Medipharma Ltd Compostos tricíclicos e uso dos mesmos
EP4289848A4 (fr) * 2021-02-03 2024-08-07 Tuojie Biotech (Shanghai) Co., Ltd. Inhibiteur de kinase cycline-dépendante tricyclique condensé, son procédé de préparation et son utilisation pharmaceutique

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7413751B2 (en) * 2001-10-25 2008-08-19 Depomed, Inc. Methods of treatment using a gastric retained losartan dosage
BRPI0615930A2 (pt) 2005-09-15 2016-08-23 Painceptor Pharma Corp métodos de modular a interação de uma neurotrofina e um receptor de neurotrofina, de tratar dor em um indivíduo, de tratar distúrbio inflamatório em um indivíduo, de tratar um distúrbio neurológico em um indivíduo, e de tratar uma doença ou distúrbio associado aos sistemas geniturinário e/ou gastrointestinal de um indivíduo, e, composto
PL2121687T3 (pl) * 2006-12-22 2016-03-31 Astex Therapeutics Ltd Pochodne amin tricyklicznych jako inhibitory białkowej kinazy tyrozynowej
EP2002836B1 (fr) * 2007-05-31 2010-10-20 Nerviano Medical Sciences S.r.l. Azaindoles cyclocondensés actifs en tant qu'inhibiteurs de la kinase
SG190361A1 (en) 2010-11-23 2013-06-28 Abbvie Inc Salts and crystalline forms of an apoptosis-inducing agent
CA2828478C (fr) 2011-02-28 2019-12-31 Array Biopharma Inc. Inhibiteurs de serine/threonine kinase
BR112014002675A2 (pt) 2011-08-04 2017-02-21 Array Biopharma Inc "quinazolina como inibidores de serina/treonina quinase, seus usos, e composição"
ES2857649T3 (es) 2012-03-01 2021-09-29 Array Biopharma Inc Inhibidores de serina/treonina cinasa
JP6378182B2 (ja) 2012-08-27 2018-08-22 アレイ バイオファーマ、インコーポレイテッド 過剰増殖性│疾患の処置のためのセリン／スレオニンキナーゼ阻害剤
WO2014060395A1 (fr) 2012-10-16 2014-04-24 F. Hoffmann-La Roche Ag Inhibiteurs de la sérine/thréonine kinase
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
AU2014360455B2 (en) 2013-12-06 2018-05-10 Genentech, Inc. Serine/threonine kinase inhibitors
KR102396710B1 (ko) 2013-12-30 2022-05-10 어레이 바이오파마 인크. 세린/트레오닌 키나제 저해제
JP6487925B2 (ja) 2013-12-30 2019-03-20 ジェネンテック， インコーポレイテッド セリン／トレオニンキナーゼ阻害剤
EP3129025B1 (fr) 2014-04-09 2019-05-15 Genentech, Inc. Procédé de fabrication de médicaments

Also Published As

Publication number Publication date
AU2014360455A1 (en) 2016-07-07
UA120506C2 (uk) 2019-12-26
MY176049A (en) 2020-07-22
PH12016501071A1 (en) 2016-07-25
EA201691177A1 (ru) 2016-10-31
MA39170A1 (fr) 2018-04-30
CA2932729A1 (fr) 2015-06-11
IL246017A0 (en) 2016-08-02
EA031243B1 (ru) 2018-12-28
SG11201604573WA (en) 2016-07-28
MX368443B (es) 2019-10-02
JP2016539153A (ja) 2016-12-15
JP6449293B2 (ja) 2019-01-09
EP3077401B1 (fr) 2018-04-18
TWI557126B (zh) 2016-11-11
BR112016012844B1 (pt) 2023-01-10
PH12016501071B1 (en) 2019-04-26
ZA201604461B (en) 2022-05-25
US10278975B2 (en) 2019-05-07
CN106029672B (zh) 2019-03-29
US20180000833A1 (en) 2018-01-04
WO2015085007A1 (fr) 2015-06-11
AU2014360455B2 (en) 2018-05-10
NZ721361A (en) 2021-07-30
KR20160093703A (ko) 2016-08-08
MX2016007352A (es) 2016-09-08
CR20160309A (es) 2016-08-25
CL2016001368A1 (es) 2016-12-09
TW201522338A (zh) 2015-06-16
CA2932729C (fr) 2021-02-23
EP3077401A1 (fr) 2016-10-12
PE20160886A1 (es) 2016-09-14
AR098647A1 (es) 2016-06-01
US11376260B2 (en) 2022-07-05
US20150182537A1 (en) 2015-07-02
CN106029672A (zh) 2016-10-12
US9867833B2 (en) 2018-01-16
BR112016012844A2 (fr) 2017-08-08
US20190192534A1 (en) 2019-06-27
JP2019034970A (ja) 2019-03-07
US10517878B2 (en) 2019-12-31
IL246017B (en) 2019-10-31
KR102359759B1 (ko) 2022-02-09
US20210106593A1 (en) 2021-04-15
US20200078371A1 (en) 2020-03-12
US10842799B2 (en) 2020-11-24

Similar Documents

Publication Publication Date Title
MA39170B1 (fr) Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer
MA42109A (fr) Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
CA2871471C (fr) Inhibiteurs d'adn pk
MA41251B1 (fr) Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
MX383213B (es) Inhibidores de tirosina-cinasas
MA39211A1 (fr) Composés tricycliques comme agents anti-cancers
EA201692166A1 (ru) Гетероциклические ингибиторы глютаминазы
EA201490493A1 (ru) Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы
MX2014002683A (es) Derivados de benzonitrilo como inhibidores de cinasa.
MA34797B1 (fr) Hétéroaryles et leurs utilisations
EA201790818A1 (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы bace1
MA37439A1 (fr) Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1).
MA35895B1 (fr) Inhibiteurs d'iap
EA201590268A1 (ru) Ариллактамные ингибиторы киназы
EA201790206A1 (ru) Новые 2,5-замещенные пиримидины в качестве ингибиторов pde4
EA201591180A1 (ru) Составы ингибитора lfa-1
EA201590787A1 (ru) Замещенные пиридопиразины в качестве ингибиторов syk
EA201501187A1 (ru) Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
MA38009A1 (fr) Composes d'azaindoline substitues qui ont une activite inhibitrice de la proteine d'apoptose pour leurs utilisations dans le traitement et/ou la prophylaxie du cancer
EA201500736A1 (ru) Пиразолилкарбоксамиды i в качестве ингибиторов crac каналов
EA201500737A1 (ru) Пиразолилкарбоксамиды ii в качестве ингибиторов crac каналов
MX2015009678A (es) Compuestos de pirimidina condensada sustituida con amino en la posicion 4 como inhibidores de fosfodiesterasa 4 (pde4).
MA38591A1 (fr) Héteroaryldihydropyrimidines pontées en position 6 pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b